Fagerstrom Test Calculator

The Fagerstrom Test for Nicotine Dependence (FTND) is a 6-item standardized questionnaire that quantifies the intensity of physical addiction to nicotine, developed in 1991 as a revision of the original Fagerstrom Tolerance Questionnaire. The test produces scores ranging from 0-10 points, with higher scores indicating greater nicotine dependence. Score interpretation: 0-2 points: Very low dependence - Minimal physical addiction, predominantly psychological habit. These smokers typically consume fewer than 10 cigarettes daily, smoke their first cigarette more than 60 minutes after waking, and can abstain easily in smoke-free environments. Cessation success rates with behavioral support alone exceed 20-30%, often without needing pharmacotherapy. 3-4 points: Low dependence - Mild nicotine addiction with moderate withdrawal symptoms upon cessation. These individuals smoke 11-20 cigarettes daily, have first cigarette 31-60 minutes after waking, and experience mild cravings when unable to smoke. Combination of behavioral counseling plus nicotine replacement therapy (NRT) increases quit rates to 15-25%. 5 points: Moderate dependence - Significant nicotine addiction requiring structured treatment. Smokers typically consume 20-30 cigarettes daily (pack to pack-and-a-half), smoke within 6-30 minutes of waking, and experience strong cravings and irritability without cigarettes. Pharmacotherapy (varenicline, bupropion, or NRT) combined with counseling yields 20-30% 6-month abstinence rates. 6-7 points: High dependence - Severe nicotine addiction with pronounced withdrawal symptoms. These individuals smoke 21-30 cigarettes daily, light up within 5-30 minutes of waking (often before getting out of bed), find it very difficult to refrain from smoking in restricted areas, and smoke even when ill. Intensive treatment with combination pharmacotherapy (e.g., nicotine patch plus gum/lozenge) plus intensive counseling is recommended, achieving 15-20% long-term quit rates. 8-10 points: Very high dependence - Extremely severe addiction with heavy daily smoking (30+ cigarettes, 1.5-2+ packs), first cigarette within 5 minutes of waking, chain-smoking patterns, and smoking throughout illness. These smokers often wake during the night to smoke and experience severe withdrawal (agitation, depression, concentration difficulties) within hours of last cigarette. Require aggressive multimodal treatment: combination NRT, behavioral therapy, possible prescription medications (varenicline at higher doses), and consideration of specialist addiction services. Long-term quit rates are 5-15% even with intensive treatment, often requiring multiple quit attempts. The FTND score predicts both withdrawal severity and appropriate treatment intensity—higher scores necessitate more aggressive pharmacological and behavioral interventions to achieve successful cessation.

The FTND consists of six specific questions with weighted point values based on their correlation with nicotine dependence: Question 1: How soon after you wake up do you smoke your first cigarette? This is the most predictive single item of nicotine dependence. Scoring: Within 5 minutes = 3 points; 6-30 minutes = 2 points; 31-60 minutes = 1 point; After 60 minutes = 0 points. Rationale: Highly dependent smokers experience overnight nicotine withdrawal and need immediate replenishment upon waking. Smoking within 5 minutes indicates very high addiction—nicotine levels have dropped significantly overnight, and the smoker cannot complete basic morning routines before smoking. Question 2: Do you find it difficult to refrain from smoking in places where it is forbidden (e.g., church, library, movie theater)? Scoring: Yes = 1 point; No = 0 points. This assesses the strength of cravings and ability to delay gratification. Highly dependent smokers experience intense discomfort in smoke-free environments and may leave early or violate restrictions. Question 3: Which cigarette would you hate most to give up? Scoring: The first one in the morning = 1 point; Any other = 0 points. The morning cigarette is most valued by dependent smokers because it relieves overnight withdrawal. Those who value other cigarettes more (e.g., after meals, with coffee) tend to have lower physical dependence, with smoking being more ritualistic/habitual. Question 4: How many cigarettes per day do you smoke? Scoring: 31 or more = 3 points; 21-30 = 2 points; 11-20 = 1 point; 10 or fewer = 0 points. Daily consumption directly correlates with nicotine exposure and dependence. Heavy smokers (30+ cigarettes) typically have FTND scores of 7-10. Question 5: Do you smoke more frequently during the first hours after waking than during the rest of the day? Scoring: Yes = 1 point; No = 0 points. Morning smoking intensity reflects overnight nicotine depletion. Dependent smokers front-load their smoking after waking—often smoking 2-3 cigarettes in the first hour versus 1 per hour later in the day—to rapidly restore nicotine levels. Question 6: Do you smoke even if you are so ill that you are in bed most of the day? Scoring: Yes = 1 point; No = 0 points. Smoking during significant illness (fever, flu, respiratory infection) indicates compulsive use despite negative consequences—a hallmark of addiction. Non-dependent smokers readily abstain when ill. Example scoring: A smoker who: smokes first cigarette 10 minutes after waking (2 points), finds it difficult to refrain in forbidden places (1 point), values morning cigarette most (1 point), smokes 25 cigarettes daily (2 points), smokes more in morning (1 point), and smokes when ill (1 point) scores 8 points = very high dependence. This person requires intensive cessation support with combination pharmacotherapy. Questions 1 and 4 carry the most weight (0-3 points each), contributing 6 of 10 total points, as time-to-first-cigarette and daily consumption are the strongest predictors of dependence severity.

FTND scores directly inform evidence-based treatment planning, with higher scores requiring more intensive interventions: Score 0-2 (Very Low Dependence): Behavioral counseling alone may suffice. Recommend: (1) Brief physician advice (5-minute intervention doubles quit rates from 5% to 10%); (2) Self-help materials and mobile apps; (3) Identify smoking triggers and develop coping strategies; (4) Set quit date and inform support network; (5) Consider short-term NRT (2-4 weeks) if cravings emerge, though not always necessary. These smokers often succeed with "cold turkey" approaches, achieving 15-25% 6-month abstinence with minimal support. Score 3-4 (Low Dependence): Behavioral support plus single NRT. Recommend: (1) Weekly counseling sessions for 4-8 weeks; (2) Choose one NRT: nicotine patch (21 mg/day for 6 weeks, then taper to 14 mg for 2 weeks, then 7 mg for 2 weeks), or nicotine gum 2-4 mg as needed (8-12 pieces daily), or nicotine lozenge 2-4 mg every 1-2 hours; (3) Cognitive-behavioral therapy targeting smoking triggers; (4) Treatment duration: 8-12 weeks NRT. Expected 6-month quit rate: 20-30%. Score 5 (Moderate Dependence): Prescription medication or combination NRT. First-line options: (1) Varenicline (Chantix): 0.5 mg daily days 1-3, 0.5 mg twice daily days 4-7, then 1 mg twice daily for 12 weeks. Increases quit rates to 33-44%. Partial nicotine receptor agonist that reduces cravings and blocks rewarding effects of smoking. (2) Bupropion (Zyban): 150 mg daily for 3 days, then 150 mg twice daily for 12 weeks. Start 1-2 weeks before quit date. Quit rates 25-30%. Contraindicated with seizure history. (3) Combination NRT: Patch (21 mg) for baseline nicotine levels plus gum/lozenge for breakthrough cravings. Increases success by 30-40% versus single NRT. Plus weekly counseling. Score 6-7 (High Dependence): Intensive combination therapy. Recommend: (1) Varenicline at standard dose or bupropion; (2) Combination NRT (if not using varenicline): 21 mg patch + 4 mg gum/lozenge (use 9-12 pieces daily), or 42 mg patch for very heavy smokers; (3) Intensive counseling: weekly for 8 weeks, then biweekly for 4 weeks; (4) Extended treatment duration: 24-52 weeks of NRT to prevent relapse; (5) Address co-morbid conditions (depression, anxiety, ADHD) that impede cessation; (6) Consider group therapy or formal cessation programs; (7) Relapse prevention planning. Quit rates: 20-30% at 6 months with intensive treatment. Score 8-10 (Very High Dependence): Maximum intensity multimodal treatment. Recommend: (1) Higher-dose varenicline: Consider 1 mg three times daily (off-label) or extending to 24 weeks if effective; (2) Combination NRT at high doses: 42 mg patch plus multiple gum/lozenge uses throughout day (15-20 pieces); (3) Intensive behavioral counseling: weekly for 12 weeks minimum, continue monthly for 6-12 months; (4) Contingency management with incentives for biochemically-verified abstinence; (5) Address psychiatric co-morbidities aggressively—50-60% of highly dependent smokers have depression/anxiety; (6) Consider inpatient or intensive outpatient addiction programs for smokers with failed multiple attempts; (7) Long-term maintenance NRT (1-2 years) to prevent relapse; (8) E-cigarettes as harm reduction if complete cessation fails repeatedly. Even with maximal treatment, long-term quit rates are 10-20%, and multiple quit attempts (average 6-8) are typically needed. Cost-effectiveness: Intensive treatment for high-dependence smokers costs $2,000-5,000 but prevents smoking-related disease costs of $50,000-100,000, making it highly cost-effective.

FTND scores strongly predict withdrawal severity, helping clinicians anticipate and manage symptoms during cessation attempts. Withdrawal syndrome begins within 2-4 hours of last cigarette, peaks at 48-72 hours, and gradually resolves over 2-4 weeks, though psychological cravings persist months to years. FTND 0-2 (Very Low): Minimal withdrawal - May experience mild cravings, slight irritability, and minor concentration difficulties for 3-7 days. Most symptoms are manageable without pharmacotherapy. Sleep disturbance and appetite changes are uncommon. These smokers often report that quitting is easier than expected. FTND 3-4 (Low): Mild withdrawal - Moderate cravings lasting 1-2 weeks, irritability, restlessness, difficulty concentrating, increased appetite (2-5 pound weight gain typical), and mild depressed mood. Symptoms peak days 2-3 and resolve substantially by week 2. NRT reduces symptom intensity by 30-50%, making symptoms tolerable. FTND 5 (Moderate): Moderate withdrawal - Strong cravings lasting 3-4 weeks with gradual decline, significant irritability and anger outbursts, anxiety, difficulty concentrating (may impair work performance), insomnia or hypersomnia, increased appetite (5-10 pound weight gain common), constipation, depressed mood. Peak symptoms days 3-5. Without treatment, symptoms are quite distressing and cause 40-60% of quit attempts to fail within first week. Combination NRT or prescription medication reduces symptom severity by 50-70%. FTND 6-7 (High): Severe withdrawal - Intense, persistent cravings lasting 4-8 weeks, severe irritability with potential aggression, marked anxiety with panic attack symptoms, significant depression (20-30% develop major depressive episode), severe concentration and memory deficits, strong insomnia or excessive sleepiness, restlessness and motor tension, appetite increase with 8-15 pound weight gain, headaches, dizziness. Peak intensity days 3-7, with very gradual improvement over 4-6 weeks. Untreated withdrawal is debilitating, with 70-80% relapse within 72 hours. Combination pharmacotherapy essential, reducing symptoms by 60-80% but not eliminating them. FTND 8-10 (Very High): Extremely severe withdrawal - Overwhelming cravings described as "unbearable," extreme irritability with rage episodes, severe anxiety with possible panic disorder, major depression with suicidal ideation (5-10% of cases), profound concentration deficits rendering work/driving impaired, severe insomnia (2-4 hours sleep nightly) alternating with daytime fatigue, tremors and muscle tension, appetite disruption (some overeat, others lose appetite), headaches, flu-like symptoms. Symptoms peak days 4-7 but remain severe for 2-3 weeks, with substantial symptoms persisting 6-8 weeks. Even with maximum pharmacotherapy (combination NRT or high-dose varenicline), withdrawal remains quite uncomfortable, and 60-70% relapse within 2 weeks. May require temporary work accommodation, close medical monitoring, and psychiatric consultation if depression/suicidality emerge. Nicotine replacement dosing by FTND score: FTND 3-4: 14 mg patch or 2 mg gum/lozenge sufficient. FTND 5-6: 21 mg patch or 4 mg gum/lozenge. FTND 7-8: 21-42 mg patch plus 4 mg gum/lozenge as needed. FTND 9-10: 42 mg patch plus frequent 4 mg gum/lozenge (every 1-2 hours), or consider varenicline 1 mg three times daily. Varenicline effectiveness by FTND: More effective in higher dependence—FTND 7-10 smokers achieve 30-40% quit rates with varenicline versus only 10-15% with placebo, a larger absolute benefit than seen in low-dependence smokers.

The FTND has strong psychometric properties with good reliability and validity, but also important limitations: Reliability: Internal consistency (Cronbach's alpha) = 0.61-0.64, considered acceptable though not excellent—items measure a common construct (physical dependence) but also capture somewhat distinct aspects. Test-retest reliability = 0.85-0.88 over 1-2 weeks, indicating stable measurement over short periods. Scores may fluctuate during quit attempts or changes in smoking behavior. Validity: Concurrent validity—FTND correlates strongly with biochemical nicotine markers: cotinine levels (r = 0.60-0.70), exhaled carbon monoxide (r = 0.55-0.65), and cigarettes per day (r = 0.75). Predictive validity—higher scores predict lower quit rates, higher relapse risk, and more severe withdrawal, with hazard ratios of 1.3-1.5 per point increase for relapse within 6 months. Construct validity—FTND measures physical dependence distinct from psychological dependence or social/environmental factors. Strengths: (1) Brief administration—6 questions completed in 2-3 minutes, feasible in busy clinical settings; (2) Easy scoring—simple additive scale without complex calculations; (3) Strong predictive power—time-to-first-cigarette and cigarettes-per-day (worth 6 of 10 points) strongly predict cessation outcomes; (4) Widely validated—used in hundreds of studies across diverse populations; (5) Translated into 50+ languages with demonstrated validity internationally; (6) Public domain—no licensing fees, freely available. Limitations: (1) Focus on physical dependence only—doesn't assess psychological dependence (e.g., smoking for stress relief, boredom, social connection), cognitive aspects (automaticity, cue reactivity), or motivation to quit. A smoker may have low FTND score but strong psychological dependence making quitting difficult. (2) Ceiling effect—maximum score of 10 doesn't distinguish very heavy smokers. Someone smoking 40 cigarettes/day may score the same as someone smoking 120 cigarettes/day (both get 3 points on question 4), despite different dependence levels. (3) Not sensitive to change—score changes minimally during quit attempts or with treatment, limiting utility for monitoring progress. Better suited for baseline assessment than longitudinal tracking. (4) Developed for cigarettes—validity questionable for other tobacco products: cigars, pipes, smokeless tobacco, e-cigarettes. Questions about "first cigarette" don't translate well to cigar smokers who may not inhale. (5) Cultural/demographic factors—may underestimate dependence in populations with lower daily consumption due to financial constraints or social restrictions. A smoker who would smoke 30 cigarettes/day but can only afford 15 may be scored as lower dependence than actual. (6) Binary/categorical items—questions 2, 3, 5, 6 are yes/no, lacking nuance. Distinction between "difficult" and "very difficult" to refrain from smoking isn't captured. (7) Omits important dependence features—doesn't assess continued smoking despite harm, tolerance (needing more cigarettes for same effect), or time spent obtaining/using cigarettes. Complementary assessments: For comprehensive evaluation, supplement FTND with: (1) Motivation to quit—readiness to change scales (precontemplation, contemplation, preparation, action); (2) Psychiatric co-morbidity—depression (PHQ-9), anxiety (GAD-7), ADHD screening; (3) Prior quit attempts—number, duration, methods used, reasons for relapse; (4) Social support and barriers—household smokers, workplace smoking, social smoking patterns; (5) Biochemical verification—exhaled CO, urine/saliva cotinine for objective nicotine exposure. Despite limitations, FTND remains the gold standard brief assessment for nicotine dependence in clinical practice, efficiently identifying patients needing intensive intervention.

The FTND requires interpretation adjustments for special populations where standard scoring may not fully capture dependence or treatment needs: Light smokers (non-daily or <10 cigarettes/day): These individuals often score 0-3 (very low to low dependence) on FTND, potentially leading clinicians to assume cessation will be easy. However, light smoking carries significant health risks—1-4 cigarettes daily increases cardiovascular disease risk by 50-60% and lung cancer risk by 3-fold compared to never-smokers. Many light smokers have strong psychological dependence (smoking for stress, socializing) despite low physical dependence. Modified approach: Even with FTND 0-2, offer: (1) Brief behavioral counseling emphasizing health risks of light smoking; (2) Cognitive-behavioral therapy targeting situational triggers; (3) Short-term NRT (4-8 weeks) for breakthrough cravings, even if not strictly "indicated" by score; (4) Address misconceptions that light smoking is "safe" or quitting will be trivial. Studies show light smokers have 5-15% quit rates, comparable to heavier smokers in some studies, because psychological attachment is strong. Pregnant women: FTND scores often underestimate actual dependence because many pregnant women reduce smoking due to nausea (first trimester) or health concerns, lowering daily consumption and time-to-first-cigarette temporarily. A pregnant smoker scoring FTND 3-4 may have been 6-7 pre-pregnancy. Modified approach: (1) Ask about pre-pregnancy smoking patterns to assess true dependence level; (2) Strongly emphasize behavioral counseling as first-line—behavioral interventions increase quit rates from 5% to 10-15% without medication risks; (3) NRT is Category D (human risk evidence) but safer than continued smoking—consider for FTND ≥5 after failed behavioral attempts, using lowest effective dose (14 mg patch or intermittent gum/lozenge rather than 24-hour patch exposure); (4) Varenicline and bupropion are generally avoided in pregnancy unless benefits clearly outweigh risks; (5) Intensive support—weekly counseling, home visits, contingency management with financial incentives (effective in pregnant women). Even low FTND scores warrant aggressive intervention due to fetal harm from any smoking. Adolescents (ages 12-17): Adolescent dependence develops rapidly but differently than adults—some show dependence symptoms after smoking only 100 lifetime cigarettes. However, FTND may underestimate adolescent dependence because: (1) Lower daily consumption due to school restrictions, lack of money, parental supervision; (2) Social/weekend smoking patterns not captured by daily cigarette questions; (3) Adolescent-specific withdrawal symptoms (mood disturbance, concentration deficits affecting school) not fully assessed. Modified approach: (1) Use adolescent-specific measures like mFTQ (modified Fagerstrom Tolerance Questionnaire) or HONC (Hooked on Nicotine Checklist) alongside FTND; (2) Lower threshold for intervention—consider NRT for FTND ≥3 in adolescents versus ≥5 in adults; (3) Address peer and family influences—family therapy if parents smoke; (4) School-based programs and mobile app interventions; (5) Shorter NRT duration (6-8 weeks) as adolescents may have shorter dependence history. Elderly smokers (65+): Often score higher on FTND due to decades of smoking, but may have strong motivation to quit after health scares. Considerations: (1) Polypharmacy concerns—check for interactions between cessation medications and existing prescriptions; (2) Adjust NRT dosing in renal/hepatic impairment; (3) Cognitive impairment may affect adherence to complex regimens—simplify to single daily patch if needed; (4) Emphasize immediate health benefits (improved cardiovascular function within weeks, reduced infection risk) rather than long-term cancer prevention. Dual users (cigarettes + e-cigarettes): FTND focuses on cigarettes but doesn't capture nicotine from vaping. Total nicotine dependence may be higher than FTND indicates. Approach: (1) Assess total nicotine intake from all sources; (2) If using high-nicotine e-cigarettes plus cigarettes, consider treating as high dependence even if FTND moderate; (3) Some evidence supports transitioning completely to e-cigarettes as harm reduction when complete cessation fails. Smokers with psychiatric illness: Prevalence of smoking is 40-50% in depression, 50-60% in schizophrenia, 35-45% in ADHD—much higher than general population (15-20%). FTND scores are typically 1-2 points higher than general population. Key considerations: (1) Smoking cessation may precipitate or worsen depression/anxiety—close monitoring and possible antidepressant adjustment; (2) Bupropion has dual benefit (cessation + antidepressant); (3) Varenicline controversial in psychiatric illness due to neuropsychiatric side effects but recent data suggests safety with monitoring; (4) Combination therapy essential—psychiatric symptoms plus nicotine withdrawal create high relapse risk without aggressive pharmacological support.